UNICYCIVE THERAPEUTICS, INC. Finance Lease, Right-of-Use Asset, Amortization
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Finance Lease, Right-of-Use Asset, Amortization of $268.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2022-05-12
- UNICYCIVE THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2022-03-31 was $268.00K.
- UNICYCIVE THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2021 was $305.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|
| 2022-03-31 | $268.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $305.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |